Growing Diagnostics RICOVR Healthcare is developing the XALIVA rapid diagnostics platform powered by saliva with a roadmap of point‑of‑care tests for drugs of abuse, reproductive health, infectious diseases, and THC. This presents a near‑term sales opportunity to healthcare providers, occupational health programs, correctional facilities, and schools seeking fast, noninvasive screening solutions.

NIH Funding Potential Recent NIH SBIR grant activity indicates government funding alignment for scalable, accurate device development. This signals potential for contract‑level collaborations, pilot programs, and validation studies with public sector and research institutions, creating entry points for large‑scale procurement channels.

Strategic Partnerships strong partnerships with leading research institutions and medical device manufacturers expand credibility and distribution reach. Leverage partner networks to accelerate adoption in clinical labs, ambulatory care, and enterprise health programs while co‑selling integrated diagnostics solutions.

Recognition & Momentum Awards and industry visibility, including Civil Rights Trailblazer recognition and selection for global entrepreneurship events, enhance credibility with potential customers and investors. Use these milestones to open conversations with healthcare systems, employers, and law enforcement agencies evaluating rapid screening capabilities.

Expanded Commercial Focus Product pipeline targeting diverse point‑of‑care markets and a compact, portable detection platform aligns with demand for decentralized testing. Target mid‑sized health systems, occupational health services, and public safety agencies seeking scalable, cost‑effective testing that minimizes sample burden and accelerates decision‑making.